Is Dermata Therapeutics going out of business?

Dermata Therapeutics, Inc. (DRMA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Dermata Therapeutics, Inc. (DRMA) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

2-3 mo of estimated runway from 2026-06-30, based on $4.4M of cash and short-term investments against $21.7M of annual burn. Adjusted shares outstanding increased 410.2% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: Reverse split detected; adjusted share change (410.2% YoY) and the capital-structure risk is penalized.
• Filing event risk: Going-Concern Warning (-8 pts)
• Return on Assets: -142.06%
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-08-17.

Price as of 2026-09-07.